AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
May 01, 2018- Application supported by four pivotal Phase 3 trials evaluating more than 2,000 patients with moderate to severe plaque psoriasis (1-3)
-
April 27, 2018- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids
-
April 26, 2018- Reports First-Quarter Diluted EPS of $1.74 on a GAAP Basis; Adjusted Diluted EPS of $1.87 Reflects Growth of 46.1 Percent
-
April 25, 2018- In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1)
-
April 25, 2018- In SELECT-SUNRISE, upadacitinib met the primary endpoint of ACR20 across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at week 12, with a significant difference in ACR20 compared to placebo observed as early as week one(1)
-
April 10, 2018- FDA requires extended time for review of additional information in New Drug Application (NDA)
-
April 09, 2018- In SELECT-COMPARE, upadacitinib (15 mg, once-daily) met both primary endpoints, with 71 percent of patients achieving ACR20 and 29 percent achieving clinical remission at week 12 (1)
-
April 06, 2018
-
April 05, 2018- Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates
-
March 22, 2018- AbbVie will not seek accelerated approval for Rova-T in third-line relapsed/refractory small cell lung cancer (SCLC)
-
March 21, 2018- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally
-
March 13, 2018− Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints
-
March 05, 2018- Endometriosis affects an estimated one in 10 women of reproductive age, but diagnosis can take up to six to 10 years(1,2)
-
February 26, 2018
-
February 21, 2018− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints
-
February 20, 2018Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau
-
February 17, 2018- At week 16, 37 and 51 percent of patients with plaque psoriasis treated with risankizumab achieved clear skin (sPGA 0) compared to STELARA® (ustekinumab) (14 and 25 percent)(1)
-
February 17, 2018- Upadacitinib showed a reduction in itch (pruritus) as early as Week 1(1)
-
February 16, 2018- Results from the 52-week CELEST study showed that many upadacitinib-treated patients who achieved clinical response§ after the study's 16-week induction phase maintained their response to treatment after the 36-week extension phase(1)
-
February 15, 2018
-
February 12, 2018- Fourteen presentations of HUMIRA® (adalimumab) and pipeline data demonstrate AbbVie's extensive dermatology portfolio and continued commitment to patients living with immune-mediated diseases
-
January 26, 2018- Reports Full-Year Diluted EPS of $3.30 on a GAAP Basis; Adjusted Diluted EPS of $5.60 Reflects Growth of 16.2 Percent
-
January 12, 2018
-
January 08, 2018- Breakthrough Therapy Designation is granted to investigational treatments for serious diseases with preliminary clinical evidence that the treatment may demonstrate substantial improvement over existing therapies (1)
-
December 20, 2017
-
December 20, 2017- SELECT-MONOTHERAPY, the third study in the robust SELECT program, showed positive results, with both doses (15 mg and 30 mg once-daily) meeting the primary endpoints in patients with an inadequate response to methotrexate(1)
-
December 12, 2017- Phase 3 MURANO results presented for the first time today as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA
-
December 11, 2017- Clinical results suggest that ibrutinib inhibits B cells and follicular helper T cells believed to play a critical role in treating chronic graft-versus-host disease (cGVHD), while preserving immune memory and Th1 T cells
-
December 09, 2017- Nearly half of all R/R MCL patients in the pooled analysis were able to survive their disease at three years and more than one quarter of patients had no progression in their disease
-
December 09, 2017- Follow-up data from RESONATE™-2 suggest long-term benefits of ibrutinib as a first-line therapy in CLL, via the longest patient-reported outcomes to date and a progression-free survival rate of 85 percent
-
December 05, 2017- The iNNOVATE study included newly and previously-treated patients with Waldenström's macroglobulinemia (WM) and will support discussions with regulatory authorities
-
December 04, 2017- Risankizumab met all co-primary and ranked secondary endpoints in fourth pivotal Phase 3 study; no new safety signals detected across the Phase 3 program for plaque psoriasis1-4*
-
November 21, 2017- Full results from investigational Phase 3 MURANO study of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) to be presented for the first time in late-breaking session
-
November 03, 2017
-
November 01, 2017- In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
-
October 27, 2017- Reports Third-Quarter Diluted EPS of $1.01 on a GAAP Basis; Adjusted Diluted EPS of $1.41, Reflecting Growth of 16.5 Percent
-
October 27, 2017
-
October 27, 2017- FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease
-
October 26, 2017- First Phase 3 clinical trials reported positive results for risankizumab with 12-week dosing; no new safety signals detected across the Phase 3 program for plaque psoriasis 1,2,3
-
October 24, 2017- Thirty-eight presentations of HUMIRA® (adalimumab) and pipeline data demonstrate AbbVie's extensive immunology portfolio and continued commitment to patients living with immune-mediated inflammatory diseases
-
October 24, 2017- Collaboration combines Alector's immuno-neurology discovery platform and AbbVie's extensive research, development and commercial expertise to advance innovative new therapies for Alzheimer's disease
-
October 18, 2017
-
October 11, 2017- 16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET
-
October 09, 2017
-
September 28, 2017- Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates
-
September 27, 2017- MAVIRET is the first and only 8-week treatment for genotype 1 and 2 hepatitis C virus (HCV) infected patients without cirrhosis and who are new to DAA treatment* in Japan
-
September 18, 2017-- Results of a multicenter, open-label, randomized Phase 3 study of VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in combination with Rituxan® met the primary endpoint of prolonged progression-free survival compared with bendamustine in combination with Rituxan in patients with relapsed/refractory CLL
-
September 11, 2017- SELECT-BEYOND, the second study in the robust SELECT program, demonstrated positive results with both doses (15 mg and 30 mg once-daily) meeting the primary endpoints in a difficult-to-treat patient population, over half of whom had previously been treated with two or more biologics(1)
-
September 08, 2017
-
September 07, 2017- Study shows positive results for upadacitinib and no new safety signals detected[1]
-
September 06, 2017- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
-
August 03, 2017- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment
-
August 02, 2017- Approval for the treatment of cGVHD is the sixth U.S. disease indication for the medication and the first therapy specifically approved for adults with cGVHD after failure of one or more lines of systemic therapy
-
July 28, 2017- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*
-
July 28, 2017- Reports Second-Quarter Diluted EPS of $1.19 on a GAAP Basis; Adjusted Diluted EPS of $1.42, Reflecting Growth of 12.7 Percent
-
July 21, 2017- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy
-
June 23, 2017- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*
-
June 22, 2017
-
June 07, 2017- First Phase 3 clinical trial shows positive results for upadacitinib and a safety profile consistent with that observed in Phase 2 clinical trials (1)(2)(3)
-
June 05, 2017- IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment
-
June 05, 2017- Data show 59 percent progression free survival and 74 percent overall survival in CLL/SLL patients treated with IMBRUVICA, with high-risk patients trending to have the most favorable outcome[1]
-
May 17, 2017- Multiple new data presentations in solid tumors and hematology underscore AbbVie's growing oncology portfolio
-
May 17, 2017- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain
-
May 14, 2017- Results from data presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) further suggest that risk factors typically associated with poor clinical outcomes may be less relevant with ibrutinib treatment
-
May 09, 2017- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics
-
May 04, 2017- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics
-
April 27, 2017- Reports First-Quarter Diluted EPS of $1.06 on a GAAP Basis; Adjusted Diluted EPS of $1.28, Reflecting Growth of 11.3 Percent
-
April 21, 2017- 95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR(12) with 8 weeks of treatment(1)
-
April 20, 2017- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)
-
April 07, 2017- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids
-
April 06, 2017
-
March 30, 2017- HUMIRA is now the first-and-only biologic treatment with fingernail psoriasis data in its U.S. prescribing information for moderate to severe chronic plaque psoriasis patients
-
March 14, 2017- Priority review granted in Japan, following EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively
-
February 27, 2017- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis*
-
February 17, 2017
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
